
GLMD
US listing · $4.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +1.9% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Sep 2, 2026 | After the close | -3.12 | -2.86 | +8.3% |
| Jun 25, 2026 | Time not confirmed | -0.51 | -0.62 | -21.6% |
| Mar 31, 2026 | After the close | -0.51 | -0.92 | -80.4% |
| Nov 26, 2025 | Before the open | -0.54 | -0.33 | +38.9% |
| Aug 28, 2025 | Before the open | -0.83 | -0.63 | +24.1% |
| May 22, 2025 | Before the open | -0.89 | -0.62 | +30.3% |
| Mar 26, 2025 | Time not confirmed | — | -1.94 | — |
| Nov 20, 2024 | After the close | — | -2.31 | — |
| Aug 23, 2024 | After the close | — | -2.13 | — |
| Apr 4, 2024 | After the close | -3.84 | -2.64 | +31.3% |
| Mar 29, 2024 | Before the open | -0.32 | -0.98 | -206.3% |
| Nov 22, 2023 | After the close | -3.60 | -2.88 | +20.0% |
| Aug 9, 2023 | After the close | -4.08 | -11.40 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or…
| -179.4% |
| Jun 1, 2023 | Before the open | -1.50 | -1.09 | +27.3% |
| Mar 29, 2023 | After the close | -25.20 | -18.00 | +28.6% |
| Nov 16, 2022 | After the close | -27.90 | -37.80 | -35.5% |
| Aug 4, 2022 | Before the open | -42.75 | -27.00 | +36.8% |
| May 2, 2022 | Before the open | -58.80 | -54.00 | +8.2% |
| Nov 8, 2021 | Before the open | -68.40 | -55.80 | +18.4% |
| Aug 5, 2021 | Before the open | -75.60 | -59.40 | +21.4% |
| May 13, 2021 | Before the open | -71.10 | -68.40 | +3.8% |
| Mar 18, 2021 | Before the open | -0.36 | -0.48 | -33.3% |
| Nov 12, 2020 | Before the open | -67.80 | -57.60 | +15.0% |
| Aug 6, 2020 | Before the open | -58.32 | -46.80 | +19.8% |
| May 14, 2020 | Before the open | -66.00 | -52.20 | +20.9% |
| Mar 12, 2020 | Before the open | -0.34 | -0.39 | -14.7% |
| Nov 6, 2019 | Before the open | -55.03 | -37.80 | +31.3% |
| Aug 5, 2019 | Before the open | -38.83 | -36.00 | +7.3% |
| May 7, 2019 | Before the open | -37.29 | -30.60 | +17.9% |
| Mar 13, 2019 | Before the open | -0.13 | -0.18 | -38.5% |
| Nov 5, 2018 | Before the open | -25.20 | -9.00 | +64.3% |
| Aug 2, 2018 | Before the open | -28.54 | -30.60 | -7.2% |
| May 9, 2018 | Before the open | -41.40 | -30.60 | +26.1% |
| Mar 13, 2018 | Before the open | -0.22 | -0.27 | -22.7% |